Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents

This 2013 paper from Joseph Harding's laboratory at Washington State University is the foundational design and characterization paper for Dihexa and the basis for nearly every subsequent claim about the molecule's cognitive-enhancing properties. Building on prior work showing that the cognitive activity of angiotensin IV resides in a three-amino-acid core, the authors generated a series of metabolically stabilized analogs through N- and C-terminal modifications intended to increase hydrophobicity, resist enzymatic degradation, and improve blood-brain-barrier penetration. Among the analogs tested, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — Dihexa — emerged as the lead compound. In rats, oral Dihexa concentrated in brain tissue significantly above blood levels (P<0.001), restored Morris water maze performance in scopolamine-induced cognitive deficit models, demonstrated similar performance restoration in aged rats with established cognitive decline, and produced marked synaptogenic activity in hippocampal-neuron cultures. The authors framed Dihexa as a candidate therapeutic for Alzheimer's disease and related conditions where augmented synaptic connectivity may be beneficial. The paper is the source of the modern preclinical case for Dihexa.

This is a rodent and cell-culture characterization paper, not a clinical trial. The cognitive endpoints (Morris water maze, scopolamine reversal, aged-rat baseline restoration) are validated rodent paradigms but require substantial inferential bridging to human cognitive function or Alzheimer's disease pathology. The synaptogenesis findings are striking in magnitude but were reported in cell-culture systems with non-physiological endpoints; the "10 million times more potent than BDNF" framing that propagated from this work refers specifically to a synapse-formation-in-culture endpoint. The mechanism story has evolved since publication: the original AT4-receptor framing was subsequently displaced by the HGF / c-Met dependence demonstrated in Benoist 2014. The c-Met pathway is also implicated in tumor biology, a safety dimension this paper does not address. The paper is the foundational design study, not a comprehensive safety or efficacy program. No published human trials of Dihexa have followed in the decade-plus since this paper appeared.